Sarah Boyce, President and CEO at Avidity Biosciences, Inc. (RNA), sold 99,100 shares at $24.36 ($2.4M) on 2023-02-02, disclosed to the SEC on 2023-02-03.
Open-market sale of $2.4M RNA by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $24.27 | 900 | $22K | 0.9% |
| 2 | $24.36 | 45,879 | $1.1M | 46.3% |
| 3 | $24.36 | 45,879 | $1.1M | 46.3% |
| 4 | $24.26 | 3,221 | $78K | 3.2% |
| 5 | $24.26 | 3,221 | $78K | 3.2% |
| Total | $24.35 avg | 99,100 |
| $2.4M |
| 100% |
| Filing → |
| RNA | SELL | 2025-09-05 | $2.5M | — | Filing → |
| RNA | SELL | 2025-08-29 | $1.2M | — | Filing → |
| RNA | SELL | 2025-03-21 | $2.0M | — | Filing → |